异动解读 | 晶泰控股盘中大涨5.18%，首次全年盈利及AI平台商业化进展提振股价

异动解读

Mar 26

晶泰控股(02228)今日盘中大涨5.18%，引起了市场的广泛关注。

消息面上，公司于3月25日发布了2025年年度业绩报告，首次实现全年盈利，成为AI for Science领域首家盈利的港股上市公司。财报显示，公司当期实现营收8.03亿元，同比大幅增长201.25%；净利润1.24亿元，同比扭亏为盈。此外，公司期内现金余额高达70.69亿元，为持续研发投入提供了坚实保障。

公司的强劲增长主要得益于药物发现解决方案业务的迅猛发展，该业务在报告期内实现收入5.38亿元，同比大幅增长418.93%。同时，晶泰控股近期与DoveTree达成了一项总订单规模约470亿港元的管线合作，并获得了约4亿港元首付款，创下了人工智能新药研发(AIDD)领域订单规模的新纪录。公司还在大分子药物研发领域与礼来达成总额达3.45亿美元的多靶点战略合作及平台授权协议。

在政策层面，随着中国进入“十五五”规划周期，人工智能被提升为国家发展战略的重要支点，以“AI+”为核心框架的系统性政策为晶泰控股这样的行业领头羊带来了巨大利好。公司不仅在AI制药领域取得突破，还成功切入消费健康与新材料领域，展示了其“AI+机器人”平台的广泛商业化潜力。这些积极的基本面因素共同推动了今日股价的显著上涨。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1173204622"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173204622\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173204622?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-26 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173204622","market":"hk","top_or_hot":-1,"title":"异动解读 | 晶泰控股盘中大涨5.18%，首次全年盈利及AI平台商业化进展提振股价","media":"异动解读","content":"<p>晶泰控股(02228)今日盘中大涨5.18%，引起了市场的广泛关注。</p><p>消息面上，公司于3月25日发布了2025年年度业绩报告，首次实现全年盈利，成为AI for Science领域首家盈利的港股上市公司。财报显示，公司当期实现营收8.03亿元，同比大幅增长201.25%；净利润1.24亿元，同比扭亏为盈。此外，公司期内现金余额高达70.69亿元，为持续研发投入提供了坚实保障。</p><p>公司的强劲增长主要得益于药物发现解决方案业务的迅猛发展，该业务在报告期内实现收入5.38亿元，同比大幅增长418.93%。同时，晶泰控股近期与DoveTree达成了一项总订单规模约470亿港元的管线合作，并获得了约4亿港元首付款，创下了人工智能新药研发(AIDD)领域订单规模的新纪录。公司还在大分子药物研发领域与礼来达成总额达3.45亿美元的多靶点战略合作及平台授权协议。</p><p>在政策层面，随着中国进入“十五五”规划周期，人工智能被提升为国家发展战略的重要支点，以“AI+”为核心框架的系统性政策为晶泰控股这样的行业领头羊带来了巨大利好。公司不仅在AI制药领域取得突破，还成功切入消费健康与新材料领域，展示了其“AI+机器人”平台的广泛商业化潜力。这些积极的基本面因素共同推动了今日股价的显著上涨。</p>","source":"ai_movement_cn","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | 晶泰控股盘中大涨5.18%，首次全年盈利及AI平台商业化进展提振股价</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | 晶泰控股盘中大涨5.18%，首次全年盈利及AI平台商业化进展提振股价\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092702339\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">异动解读 </p>\n<p class=\"h-time\">2026-03-26 09:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>晶泰控股(02228)今日盘中大涨5.18%，引起了市场的广泛关注。</p><p>消息面上，公司于3月25日发布了2025年年度业绩报告，首次实现全年盈利，成为AI for Science领域首家盈利的港股上市公司。财报显示，公司当期实现营收8.03亿元，同比大幅增长201.25%；净利润1.24亿元，同比扭亏为盈。此外，公司期内现金余额高达70.69亿元，为持续研发投入提供了坚实保障。</p><p>公司的强劲增长主要得益于药物发现解决方案业务的迅猛发展，该业务在报告期内实现收入5.38亿元，同比大幅增长418.93%。同时，晶泰控股近期与DoveTree达成了一项总订单规模约470亿港元的管线合作，并获得了约4亿港元首付款，创下了人工智能新药研发(AIDD)领域订单规模的新纪录。公司还在大分子药物研发领域与礼来达成总额达3.45亿美元的多靶点战略合作及平台授权协议。</p><p>在政策层面，随着中国进入“十五五”规划周期，人工智能被提升为国家发展战略的重要支点，以“AI+”为核心框架的系统性政策为晶泰控股这样的行业领头羊带来了巨大利好。公司不仅在AI制药领域取得突破，还成功切入消费健康与新材料领域，展示了其“AI+机器人”平台的广泛商业化潜力。这些积极的基本面因素共同推动了今日股价的显著上涨。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02228","symbol_name":"晶泰控股","start_time":0,"source_url":"","article_id":"1173204622","we_media_id":"1092702339","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173204622","pubTimestamp":1774489112,"columns":[],"sourceInfo":{"source_id":"ai_movement_cn","name":"异动解读"},"weMediaInfo":{"media_name":"异动解读","introduction":"个股异动一手消息解读","home_visible":1,"id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"晶泰控股今日盘中大涨5.18%，引起了市场的广泛关注。消息面上，公司于3月25日发布了2025年年度业绩报告，首次实现全年盈利，成为AI for Science领域首家盈利的港股上市公司。同时，晶泰控股近期与DoveTree达成了一项总订单规模约470亿港元的管线合作，并获得了约4亿港元首付款，创下了人工智能新药研发领域订单规模的新纪录。公司还在大分子药物研发领域与礼来达成总额达3.45亿美元的多靶点战略合作及平台授权协议。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02228":"晶泰控股"},"translate_title":"Interpretation of the change | Jingtai Holdings rose 5.18% in the intraday session, its first full-year profit and the commercialization progress of AI platform boosted its share price","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02228":1},"content_text":"晶泰控股(02228)今日盘中大涨5.18%，引起了市场的广泛关注。消息面上，公司于3月25日发布了2025年年度业绩报告，首次实现全年盈利，成为AI for Science领域首家盈利的港股上市公司。财报显示，公司当期实现营收8.03亿元，同比大幅增长201.25%；净利润1.24亿元，同比扭亏为盈。此外，公司期内现金余额高达70.69亿元，为持续研发投入提供了坚实保障。公司的强劲增长主要得益于药物发现解决方案业务的迅猛发展，该业务在报告期内实现收入5.38亿元，同比大幅增长418.93%。同时，晶泰控股近期与DoveTree达成了一项总订单规模约470亿港元的管线合作，并获得了约4亿港元首付款，创下了人工智能新药研发(AIDD)领域订单规模的新纪录。公司还在大分子药物研发领域与礼来达成总额达3.45亿美元的多靶点战略合作及平台授权协议。在政策层面，随着中国进入“十五五”规划周期，人工智能被提升为国家发展战略的重要支点，以“AI+”为核心框架的系统性政策为晶泰控股这样的行业领头羊带来了巨大利好。公司不仅在AI制药领域取得突破，还成功切入消费健康与新材料领域，展示了其“AI+机器人”平台的广泛商业化潜力。这些积极的基本面因素共同推动了今日股价的显著上涨。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}